8400 The Health Network News
6 articles
השקעה של עשרות מיליוני דולרים: תוכנית החדשנות שמשיקה טבע
Teva, a pharmaceutical giant, has launched an innovation program aimed at startups, with an investment expected to reach tens of millions of dollars. The program will introduce challenges twice a year, focusing on integrating innovation across Tevas operations, from drug discovery to logistics and marketing. Selected startups will begin pilot projects with full funding from Teva. The initiative is international but launched in Israel, in collaboration with the Israel Innovation Authority, 8400 Network, IATI, and Start-Up Nation Central. Teva aims to leverage AI technology and strengthen its ties with the Israeli biomedical ecosystem. The program aligns with Tevas Pivot to Growth strategy, emphasizing innovative products and rapid growth.
Product StagePartnersInvestment
הכיוון החדש של טבע: תשקיע עשרות מיליונים בחברות ביופארמה ישראליות
Teva Pharmaceutical Industries is shifting its focus towards innovative biopharmaceuticals, investing tens of millions of dollars annually in Israeli biopharma companies. This move is part of Tevas Pivot to Growth strategy, aiming to increase its self-developed drug segment at the expense of generic drugs. The company plans to lay off 3,000 employees globally, including around 300 in Israel, to reallocate resources towards research and development. Teva has also raised $2 billion in bonds to support its R&D efforts. The company is leveraging Israels innovation ecosystem, collaborating with local universities, hospitals, and startups. Tevas global innovation program was launched in Israel, emphasizing its commitment to integrating innovation across all business units.
InvestmentLayoffsPartners
"מועדון העילית" של תעשיית הבריאות מציג 3 פרויקטים חדשים
From innovation nation to impact nation
Cellect Biotechnology, founded by Nuriel Chirich Kasbian and Dr. Shai Yarkoni, has developed a technology called ApoGraft that allows for the mass enrichment of stem cells and more effective isolation of stem cells from any given tissue. The technology has the potential to improve the effectiveness of regenerative treatments for various diseases. Cellect has conducted over 200 human trials with a 100% success rate and is collaborating with Harvard University, Stanford University, and Washington University in St. Louis medical schools on clinical trials. The company aims to make stem cell treatments more accessible, affordable, and non-toxic. The article also mentions the establishment of a new Israeli health network called 8400, which aims to transform the health-tech ecosystem into a growth engine for Israel and accelerate cures for international health challenges. MedAware, another Israeli company, is using AI and machine learning to reduce medication errors in healthcare.
PartnersExpand
Exclusive program launched for medical industry leaders
8400 - The Health Network is a leadership training and development program for executives in the medical industry. The program aims to turn medical industry company leaders into ecosystem leaders. The project has already attracted participation from leading executives in the industry. The project is supported by aMoon Fund, Isaac Devash, Israel Biotech Fund, Teva Pharmaceutical Industries Ltd., Sol Barer, Sami Sagol, and Nir Kalkstein. The program involves 20 days of lectures, group work, and a weeklong event sponsored by the Harvard Business School. The project focuses on cross-sector collaboration, identifying bottlenecks in the industry, and finding ways to turn the health sector into a growth engine. The project also includes initiatives related to regulation, intellectual property, mentoring, and the use of medical information. The goal is to have 400 participants over eight years.
PartnersInvestment
Check Point billionaire seeks to make Israel global leader in healthcare
Billionaire Marius Nacht, co-founder of Check Point Software Technologies, has founded a nonprofit organization called 8400 Health Network to make Israel a global leader in healthcare technology. The organization aims to gather experts in health and technology to drive innovation and development in the field. Israel is already known for its research and development in the medical and biotech industry, and the goal is to further expand its impact. The 8400 program has recruited its first cohort of healthcare professionals, entrepreneurs, and government officials to promote the industry and address challenges such as funding gaps and regulatory hurdles. The potential for growth in Israels healthcare startups is significant.
InvestmentExpand
